Filter Results
:
(3,383)
Show Results For
-
All HBS Web
(3,383)
- People (9)
- News (692)
- Research (2,156)
- Events (33)
- Multimedia (26)
- Faculty Publications (1,256)
Show Results For
-
All HBS Web
(3,383)
- People (9)
- News (692)
- Research (2,156)
- Events (33)
- Multimedia (26)
- Faculty Publications (1,256)
- January 2020
- Article
The Market Reacts Quickly: Changes in Paclitaxel Vascular Device Purchasing Within the Ascension Healthcare System
By: Peter P. Monteleone, Subhash Banerjee, Priya Kothapalli, Ariel Dora Stern, Daniel Fehder, Ron Ginor, Dominic Vollmar, Edward T. A. Fry and Mark J. Pirwitz
Background. A meta-analysis of trials in endovascular therapy suggested an increased mortality associated with treatment exposure to paclitaxel. Multiple publications and corrections of prior data were performed, and the United States Food and Drug Administration has...
View Details
Monteleone, Peter P., Subhash Banerjee, Priya Kothapalli, Ariel Dora Stern, Daniel Fehder, Ron Ginor, Dominic Vollmar, Edward T. A. Fry, and Mark J. Pirwitz. "The Market Reacts Quickly: Changes in Paclitaxel Vascular Device Purchasing Within the Ascension Healthcare System." Journal of Invasive Cardiology 32, no. 1 (January 2020).
- January 17, 2022
- Article
Reducing Racial Disparities in Cancer Outcomes
By: Kathy Giusti and Richard G. Hamermesh
A disproportionate number of Black patients die from cancer in the United States. A key to addressing this problem is enrolling more Black patients in clinical trials. A strategy consisting of these three parts can help accomplish this goal: 1) centralize information...
View Details
Giusti, Kathy, and Richard G. Hamermesh. "Reducing Racial Disparities in Cancer Outcomes." Harvard Business Review (website) (January 17, 2022).
- 14 Jun 2016
- News
HBS Alumna Now Kraft Precision Medicine Accelerator’s Codirector
- 01 Jun 2018
- News
Floor It
case study with the Multiple Myeloma Research Foundation, GNS Healthcare, the Moffitt Cancer Center’s ORIEN program, and biotech firm Foundation Medicine. Rethinking Drug Trials In an adaptive platform trial, different drugs are simultaneously View Details
Keywords:
Julia Hanna; illustration by Mengxin Li
- September 1991 (Revised August 1994)
- Background Note
Note on Pharmaceutical Industry Regulation
Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,...
View Details
Keywords:
Safety;
Industry Growth;
Marketing;
Research and Development;
Health Testing and Trials;
Economics;
Pharmaceutical Industry;
United States
Emmons, Willis M., III. "Note on Pharmaceutical Industry Regulation." Harvard Business School Background Note 792-002, September 1991. (Revised August 1994.)
- September 2012 (Revised September 2012)
- Course Overview Note
Building Life Science Businesses Fall 2012: Course Outline and Syllabus
This Course Outline and Syllabus gives an overview of the Fall 2012 class Building Life Science Businesses
View Details
- 24 Apr 2014
- News
Finding a cure for cancer became a personal mission
Thai Lee (MBA 1985), president and CEO of SHI International, talks about how a family crisis led her to funding cancer research. (Published April 2014)
View Details
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords:
Health Testing and Trials;
Governing Rules, Regulations, and Reforms;
Valuation;
Product Development;
Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- 25 Apr 2014
- News
Bringing a new funding model to the life sciences industry
Andrew Farquharson (MBA 1999) wants to change the landscape for biomedical financing. The cofounder of VentureHealth, an online funding platform based in Silicon Valley, Farquharson leverages deals with investors who want access to biomedical startups. "If we can...
View Details
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- 11 Nov 2015
- Working Paper Summaries
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
- 27 May 2020
- Research & Ideas
What South Korea Teaches the World About Fighting COVID
whereas South Korea has 216 cases per million. "South Korea created a vast number of testing sites, which included not only big hospitals but local clinics and public health care facilities." What South Korea teaches us is that proactive...
View Details
- 31 Jul 2018
- Working Paper Summaries
How Does Product Liability Risk Affect Innovation? Evidence from Medical Implants
Keywords:
by Alberto Galasso and Hong Luo
- August 2013
- Course Overview Note
Building Life Science Businesses Fall 2013: Course Outline and Syllabus
This Course Outline and Syllabus gives an overview of the Fall 2013 class Building Life Science Businesses.
View Details
Keywords:
Healthcare Ventures;
Entrepreneurial Management;
Entrepreneurship;
Entrepreneurs;
Health Care and Treatment;
Health Testing and Trials;
Medical Specialties;
Health Industry;
Biotechnology Industry;
Medical Devices and Supplies Industry;
Asia;
North America;
Europe
Hamermesh, Richard G. "Building Life Science Businesses Fall 2013: Course Outline and Syllabus." Harvard Business School Course Overview Note 814-019, August 2013.
- 1996
- Chapter
The Determinants of Research Productivity in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- 18 Feb 2016
- News
Challenge Aims to Speed Drug Trials Process
The HBS Health Care Initiative is seeking innovative ideas from the science, patient, business, and medical communities on how to transform trials for precision medicine. Through the HBS Precision Trials Challenge, it aims to bring diagnostics and therapies to market...
View Details
- January 2018
- Article
The Central and Unacknowledged Role of the U.S. Food and Drug Administration in the Design and Execution of Medical Device Pivotal Trials
By: Aaron V. Kaplan and Ariel D. Stern
The introduction of new medical devices has transformed cardiovascular care in recent decades. Devices, such as heart valves, pacemakers, stents, ventricular assist devices, and implantable defibrillators, have prolonged and improved the quality of life for millions of...
View Details
Keywords:
Health Testing and Trials;
Business and Government Relations;
Governing Rules, Regulations, and Reforms;
Information Publishing;
Medical Devices and Supplies Industry;
United States
Kaplan, Aaron V., and Ariel D. Stern. "The Central and Unacknowledged Role of the U.S. Food and Drug Administration in the Design and Execution of Medical Device Pivotal Trials." JAMA Cardiology 3, no. 1 (January 2018): 5–6.